Related Experiment Video
Updated: Dec 17, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS
Angela Jerath1,2,3,4, Niall D Ferguson5,6, Brian Cuthbertson5,7,8
1Department of Anesthesia, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. Angela.Jerath@mail.utoronto.ca.
Abstract:
Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily implementable solution for providing ICU sedation. Inhaled volatile agents may also provide important pulmonary benefits for COVID-19 patients with ARDS that could improve gas exchange and reduce time spent on a ventilator. We review the use of volatile agents, and provide a technical overview and algorithm for administering inhaled volatile-based sedation in ICUs.
Related Concept Videos
Inhalational Anesthetics: Overview
Parenteral Anesthetics: Overview
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-IV
Acute Respiratory Failure-III
Cardiopulmonary Resuscitation II: ACLS Airway Management

